Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ManNAc in Subjects With Podocyte Diseases
NCT06664814Phase 2Recruiting
- Sponsor
- National Human Genome Research Institute
- Start
- Oct 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of n-acetylmannosamine in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and membranous nephropathy (MN), sponsored by National Human Genome Research Institute. Primary endpoints: Percentage reduction in urine protein/creatinine ratio at 12 weeks and Frequency of adverse events at 12 weeks. Started Oct 2026; status: recruiting.
02
Drugs
n-acetylmannosamine
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT06664814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664814.